{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:03:03Z","timestamp":1794214983949,"version":"4.8.0"},"reference-count":52,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    More than half of patients with opioid use disorder for chronic non-cancer pain (CNCP) reduced their dose through a progressive opioid withdrawal supported by a rotation to buprenorphine and\/or tramadol. The aim of this research is to analyse the long-term effectiveness of opioid deprescription taking into account the impact of sex and pharmacogenetics on the inter-individual variability. A cross-sectional study was carried out from October 2019 to June 2020 on CNCP patients who had previously undergone an opioid deprescription (\n                    <jats:italic>n<\/jats:italic>\n                    = 119 patients). Demographic, clinical (pain, relief and adverse events) and therapeutic (analgesic use) outcomes were collected. Effectiveness (&lt; 50 mg per day of morphine equivalent daily dose without any aberrant opioid use behaviour) and safety (number of side-effects) were analysed in relation to sex differences and pharmacogenetic markers impact [\n                    <jats:italic>OPRM1<\/jats:italic>\n                    genotype (rs1799971) and CYP2D6 phenotypes]. Long-term opioid deprescription was achieved in 49 % of the patients with an increase in pain relief and a reduction of adverse events. CYP2D6 poor metabolizers showed the lowest long-term opioid doses. Here, women showed a higher degree of opioid deprescription, but increased use of tramadol and neuromodulators, as well as an increased number of adverse events. Long-term deprescription was successful in half of the cases. Understanding sex and gender interaction plus a genetic impact could help to design more individualized strategies for opioid deprescription.\n                  <\/jats:p>","DOI":"10.2478\/acph-2023-0018","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T15:37:55Z","timestamp":1686584275000},"page":"227-241","source":"Crossref","is-referenced-by-count":6,"title":["Long-term deprescription in chronic pain and opioid use disorder patients: Pharmacogenetic and sex differences"],"prefix":"10.2478","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0048-9451","authenticated-orcid":false,"given":"Javier","family":"Muriel","sequence":"first","affiliation":[{"name":"Neuropharmacology applied to Pain (NED) Alicante Institute for Health and Biomedical Research (ISABIAL) , c\/Pintor Baeza, 12 03010 , Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3235-1879","authenticated-orcid":false,"given":"M\u00f3nica","family":"Escorial","sequence":"additional","affiliation":[{"name":"Neuropharmacology applied to Pain (NED) Alicante Institute for Health and Biomedical Research (ISABIAL) , c\/Pintor Baeza, 12 03010 , Alicante , Spain"},{"name":"Institute of Bioengineering , Miguel Hern\u00e1ndez University , Avda. de la Universidad s\/n, 03202 , Elche , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1854-9005","authenticated-orcid":false,"given":"C\u00e9sar","family":"Margarit","sequence":"additional","affiliation":[{"name":"Neuropharmacology applied to Pain (NED) Alicante Institute for Health and Biomedical Research (ISABIAL) , c\/Pintor Baeza, 12 03010 , Alicante , Spain"},{"name":"Pain Unit, Dr. Balmis General University Hospital , ISABIAL, c\/Pintor Baeza, 12 03010 , Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4697-2783","authenticated-orcid":false,"given":"Jordi","family":"Barrachina","sequence":"additional","affiliation":[{"name":"Neuropharmacology applied to Pain (NED) Alicante Institute for Health and Biomedical Research (ISABIAL) , c\/Pintor Baeza, 12 03010 , Alicante , Spain"},{"name":"Institute of Bioengineering , Miguel Hern\u00e1ndez University , Avda. de la Universidad s\/n, 03202 , Elche , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5590-6905","authenticated-orcid":false,"given":"Cristian","family":"Carvajal","sequence":"additional","affiliation":[{"name":"Institute of Bioengineering , Miguel Hern\u00e1ndez University , Avda. de la Universidad s\/n, 03202 , Elche , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9794-5654","authenticated-orcid":false,"given":"Domingo","family":"Morales","sequence":"additional","affiliation":[{"name":"Operations Research Centre , Miguel Hern\u00e1ndez University , Avda. de la Universidad s\/n, 03202 , Elche , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2385-3749","authenticated-orcid":false,"given":"Ana M.","family":"Peir\u00f3","sequence":"additional","affiliation":[{"name":"Neuropharmacology applied to Pain (NED) Alicante Institute for Health and Biomedical Research (ISABIAL) , c\/Pintor Baeza, 12 03010 , Alicante , Spain"},{"name":"Institute of Bioengineering , Miguel Hern\u00e1ndez University , Avda. de la Universidad s\/n, 03202 , Elche , Spain"},{"name":"Pain Unit, Dr. Balmis General University Hospital , ISABIAL, c\/Pintor Baeza, 12 03010 , Alicante , Spain"},{"name":"Clinical Pharmacology Department , Dr. Balmis General University Hospital ISABIAL , c\/Pintor Baeza, 12, 03010 Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"2026051108215244379_j_acph-2023-0018_ref_001","doi-asserted-by":"crossref","unstructured":"E. A. Salsitz, Chronic pain, chronic opioid addiction: a complex nexus, J. Med. Toxicol. 12(1) (2016) 54\u201357; https:\/\/doi.org\/10.1007\/s13181-015-0521-9","DOI":"10.1007\/s13181-015-0521-9"},{"key":"2026051108215244379_j_acph-2023-0018_ref_002","doi-asserted-by":"crossref","unstructured":"A. Schuchat, G. P. Guy, Jr. and D. Dowell, Prescription drug monitoring programs and opioid death rates-reply, JAMA 318(20) (2017) Article ID 2045; https:\/\/doi.org\/10.1001\/jama.2017.16304","DOI":"10.1001\/jama.2017.16304"},{"key":"2026051108215244379_j_acph-2023-0018_ref_003","doi-asserted-by":"crossref","unstructured":"R. Lumish, J. K. Goga and N. J. Brandt, Optimizing pain management through opioid deprescribing, J. Geront. Nurs. 44(1) (2018) 9\u201314; https:\/\/doi.org\/10.3928\/00989134-20171213-04","DOI":"10.3928\/00989134-20171213-04"},{"key":"2026051108215244379_j_acph-2023-0018_ref_004","doi-asserted-by":"crossref","unstructured":"A. Owusu Obeng, I. Hamadeh and M. Smith, Review of opioid pharmacogenetics and considerations for pain management, Pharmacotherapy 37(9) (2017) 1105\u20131121; https:\/\/doi.org\/10.1002\/phar.1986","DOI":"10.1002\/phar.1986"},{"key":"2026051108215244379_j_acph-2023-0018_ref_005","doi-asserted-by":"crossref","unstructured":"B. S. Haerian and M. S. Haerian, OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis, Pharmacogenomics 14(7) (2013) 813\u2013824; https:\/\/doi.org\/10.2217\/pgs.13.57","DOI":"10.2217\/pgs.13.57"},{"key":"2026051108215244379_j_acph-2023-0018_ref_006","doi-asserted-by":"crossref","unstructured":"J. Muriel, C. Margarit, J. Barrachina, P. Ballester, A. Flor, D. Morales, J. F. Horga, E. Fern\u00e1ndez and A. M. Peir\u00f3, Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients, Basic Clin. Pharmacol Toxicol. 124(4) (2019) 439\u2013448; https:\/\/doi.org\/10.1111\/bcpt.13155","DOI":"10.1111\/bcpt.13155"},{"key":"2026051108215244379_j_acph-2023-0018_ref_007","doi-asserted-by":"crossref","unstructured":"G. Ruano and J. A. Kost, Fundamental considerations for genetically-guided pain management with opioids based on CYP2D6 and OPRM1 polymorphisms, Pain Phys. 21(6) (2018) E611\u2013E621.","DOI":"10.36076\/ppj.2018.6.E611"},{"key":"2026051108215244379_j_acph-2023-0018_ref_008","doi-asserted-by":"crossref","unstructured":"V. Haufroid and P. Hantson, CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants, Clin Toxicol. (Philadelphia) 53(6) (2015) 501\u2013510; https:\/\/doi.org\/10.3109\/15563650.2015.1049355","DOI":"10.3109\/15563650.2015.1049355"},{"key":"2026051108215244379_j_acph-2023-0018_ref_009","doi-asserted-by":"crossref","unstructured":"K. R. Crews, A. A. Monte, R. Huddart, K. E. Caudle, E. D. Kharasch, A. Gaedigk, H. M. Dunnenberger, J. S. Leeder, J. T. Callaghan, C. F. Samer, T. E. Klein, C. E. Haidar, S. L. Van Driest, G. Ruano, K. Sangkuhl, L. H. Cavallari, D. J. M\u00fcller, C. A. Prows, M. Nagy, A. A. Somogyi and T. C. Skaar, Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy, Clin. Pharmacol. Ther. 110(4) (2021) 888\u2013896; https:\/\/doi.org\/10.1002\/cpt.2149","DOI":"10.1002\/cpt.2149"},{"key":"2026051108215244379_j_acph-2023-0018_ref_010","doi-asserted-by":"crossref","unstructured":"M. Matic, S. N. de Wildt, D. Tibboel and R. H. N. van Schaik, Analgesia and opioids: A pharmacogenetics shortlist for implementation in clinical practice, Clin. Chem. 63(7) (2017) 1204\u20131213; https:\/\/doi.org\/10.1373\/clinchem.2016.264986","DOI":"10.1373\/clinchem.2016.264986"},{"key":"2026051108215244379_j_acph-2023-0018_ref_011","doi-asserted-by":"crossref","unstructured":"B. Planelles, C. Margarit, M. D. Inda, P. Ballester, J. Muriel, J. Barrachina, R. Ajo, M. D. Esteban and A. M. Peir\u00f3, Gender based differences, pharmacogenetics and adverse events in chronic pain management, Pharmacogen. J. 20(2) (2020) 320\u2013328; https:\/\/doi.org\/10.1038\/s41397-019-0118-9","DOI":"10.1038\/s41397-019-0118-9"},{"key":"2026051108215244379_j_acph-2023-0018_ref_012","doi-asserted-by":"crossref","unstructured":"K. Goodyear, C. L. Haass-Koffler and D. Chavanne, Opioid use and stigma: The role of gender, language and precipitating events, Drug Alc. Depen. 185 (2018) 339\u2013346; https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.12.037","DOI":"10.1016\/j.drugalcdep.2017.12.037"},{"key":"2026051108215244379_j_acph-2023-0018_ref_013","unstructured":"M.-T. Ruiz-Cantero, M. Blasco-Blasco, E. Chilet-Rosell and A. M. Peir\u00f3, Gender bias in therapeutic effort: from research to health care, Farm. Hospital 44 (2020) 109\u2013113."},{"key":"2026051108215244379_j_acph-2023-0018_ref_014","doi-asserted-by":"crossref","unstructured":"S. S. Asl, A. Roointan, H. Bergen, S. Amiri, P. Mardani, N. Ashtari, R. Shabani and M. Mehdizadeh, Opioid receptors gene polymorphism and heroin dependence in Iran, Basic Clin. Neurosci. 9(2) (2018) 101\u2013106; https:\/\/doi.org\/10.29252\/nirp.bcn.9.2.101","DOI":"10.29252\/nirp.bcn.9.2.101"},{"key":"2026051108215244379_j_acph-2023-0018_ref_015","doi-asserted-by":"crossref","unstructured":"P. Bach and D. Hartung, Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders, Addict. Sci. Clin. Pract. 14(1) (2019) Article ID 30 (11 pages); https:\/\/doi.org\/10.1186\/s13722-019-0158-0","DOI":"10.1186\/s13722-019-0158-0"},{"key":"2026051108215244379_j_acph-2023-0018_ref_016","doi-asserted-by":"crossref","unstructured":"S. Sarkar, R. Lal, M. Varshney and Y. P. S. Balhara, Tramadol for maintenance in opioid dependence: A retrospective chart review, J. Opioid Manag. 13(5) (2017) 329\u2013334; https:\/\/doi.org\/10.5055\/jom.2017.0401","DOI":"10.5055\/jom.2017.0408"},{"key":"2026051108215244379_j_acph-2023-0018_ref_017","doi-asserted-by":"crossref","unstructured":"R. K. Lanier, A. Umbricht, J. A. Harrison, E. S. Nuwayser and G. E. Bigelow, Evaluation of a transdermal buprenorphine formulation in opioid detoxification, Addiction (Abingdon) 102(10) (2007) 1648\u20131656; https:\/\/doi.org\/10.1111\/j.1360-0443.2007.01944.x","DOI":"10.1111\/j.1360-0443.2007.01944.x"},{"key":"2026051108215244379_j_acph-2023-0018_ref_018","doi-asserted-by":"crossref","unstructured":"J. Muriel, C. Margarit, B. Planelles, M. J. Serralta, C. Puga, M. D. Inda, E. Cutillas, D. Morales, J. F. Horga and A. M. Peir\u00f3, OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients, Ann. N. Y. Acad. Sci. 1425(1) (2018) 82\u201393; https:\/\/doi.org\/10.1111\/nyas.13735","DOI":"10.1111\/nyas.13735"},{"key":"2026051108215244379_j_acph-2023-0018_ref_019","doi-asserted-by":"crossref","unstructured":"E. von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. G\u00f8tzsche and J. P. Vandenbroucke, The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies, J. Clin. Epidemiol. 61(4) (2008) 344\u2013349; https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2026051108215244379_j_acph-2023-0018_ref_020","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 5th ed., Washington, D.C. 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2026051108215244379_j_acph-2023-0018_ref_021","unstructured":"J. Fern\u00e1ndez-Miranda, Guide to the Treatment of Opioid Dependence, Socidrogalcohol, Palma de Mallorca 2007, p. 118."},{"key":"2026051108215244379_j_acph-2023-0018_ref_022","doi-asserted-by":"crossref","unstructured":"S. Mercadante, A. Casuccio, F. Fulfaro, L. Groff, R. Boffi, P. Villari, V. Gebbia and C. Ripamonti, Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study, J. Clin. Oncol. 19(11) (2001) 2898\u20132904; https:\/\/doi.org\/10.1200\/jco.2001.19.11.2898","DOI":"10.1200\/JCO.2001.19.11.2898"},{"key":"2026051108215244379_j_acph-2023-0018_ref_023","doi-asserted-by":"crossref","unstructured":"S. H. Jones, G. Thornicroft, M. Coffey and G. Dunn, A brief mental health outcome scale-reliability and validity of the global assessment of functioning (GAF), Br. J. Psych. 166(5) (1995) 654\u2013659; https:\/\/doi.org\/10.1192\/bjp.166.5.654","DOI":"10.1192\/bjp.166.5.654"},{"key":"2026051108215244379_j_acph-2023-0018_ref_024","doi-asserted-by":"crossref","unstructured":"H. M. McCormack, D. J. Horne and S. Sheather, Clinical applications of visual analogue scales: a critical review, Psychol. Med. 18(4) (1988) 1007\u20131019.","DOI":"10.1017\/S0033291700009934"},{"key":"2026051108215244379_j_acph-2023-0018_ref_025","doi-asserted-by":"crossref","unstructured":"R. A. Moore and H. J. McQuay, Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids, Arthr. Res. Ther. 7(5) (2005) R1046\u2013R1051; https:\/\/doi.org\/10.1186\/ar1782","DOI":"10.1186\/ar1782"},{"key":"2026051108215244379_j_acph-2023-0018_ref_026","doi-asserted-by":"crossref","unstructured":"J. Barrachina, J. Muriel, C. Margarit, B. Planelles, P. Ballester, M. Richart-Mart\u00ednez, E. Cutillas, T. Zandonai, D. Morales and A. M. Peir\u00f3, Global pain state questionnaire: Reliability, validity, and gender gap, Arch. Intern. Med. Res. 4 (2021) 91\u2013113; https:\/\/doi.org\/10.26502\/aimr.0061","DOI":"10.26502\/aimr.0061"},{"key":"2026051108215244379_j_acph-2023-0018_ref_027","doi-asserted-by":"crossref","unstructured":"P. Mozzicato, MedDRA An overview of the medical dictionary for regulatory activities, Pharm. Med. 23(2) (2009) 65\u201375; https:\/\/doi.org\/10.1007\/BF03256752","DOI":"10.1007\/BF03256752"},{"key":"2026051108215244379_j_acph-2023-0018_ref_028","doi-asserted-by":"crossref","unstructured":"W. H\u00e4user, B. Morlion, K. E. Vowles, K. Bannister, E. Buchser, R. Casale, J.-F. Chenot, G. Chumbley, A. M. Drewes, G. Dom, L. Jutila, T. O\u2019Brien, E. Pogatzki-Zahn, M. Rakusa, C. Suarez-Serrano, T. T\u00f6lle and N. Kr\u010devski \u0160kvar\u010d, European clinical practice recommendations on opioids for chronic noncancer pain \u2013 Part 1: Role of opioids in the management of chronic noncancer pain, Eur. J. Pain 25(5) (2021) 949\u2013968; https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/ejp.1736","DOI":"10.1002\/ejp.1736"},{"key":"2026051108215244379_j_acph-2023-0018_ref_029","doi-asserted-by":"crossref","unstructured":"C. Taylor, I. Crosby, V. Yip, P. Maguire, M. Pirmohamed and R. M. Turner, A review of the important role of CYP2D6 in pharmacogenomics, Genes 11(11) (2020) Article ID 1295 (22 pages); https:\/\/doi.org\/10.3390\/genes11111295","DOI":"10.3390\/genes11111295"},{"key":"2026051108215244379_j_acph-2023-0018_ref_030","doi-asserted-by":"crossref","unstructured":"A. Llerena, P. Dorado, R. Ram\u00edrez, I. Gonz\u00e1lez, M. Alvarez, E. M. Pe\u00f1as-Lled\u00f3, B. P\u00e9rez and L. R. Calzadilla, CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans, Pharmacogen. J. 12(2) (2012) 176\u2013183; https:\/\/doi.org\/10.1038\/tpj.2010.85","DOI":"10.1038\/tpj.2010.85"},{"key":"2026051108215244379_j_acph-2023-0018_ref_031","doi-asserted-by":"crossref","unstructured":"A. Gaedigk, S. D. Simon, R. E. Pearce, L. D. Bradford, M. J. Kennedy and J. S. Leeder, The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype, Clin. Pharmacol. Ther. 83(2) (2008) 234\u2013242; https:\/\/doi.org\/10.1038\/sj.clpt.6100406","DOI":"10.1038\/sj.clpt.6100406"},{"key":"2026051108215244379_j_acph-2023-0018_ref_032","doi-asserted-by":"crossref","unstructured":"P. Dorado, M. C\u00e1ceres, E. Pozo-Guisado, M. L. Wong, J. Licinio and A. Llerena, Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use, BioTechniques 39(Suppl. 10) (2005) S571\u2013S574; https:\/\/doi.org\/10.2144\/000112044","DOI":"10.2144\/000112044"},{"key":"2026051108215244379_j_acph-2023-0018_ref_033","doi-asserted-by":"crossref","unstructured":"M. E. G. Naranjo, F. de Andr\u00e9s, A. Delgado, J. Cobaleda, E. M. Pe\u00f1as-Lled\u00f3 and A. LLerena, High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies, Pharmacogen. J. 16(5) (2016) 485\u2013490; https:\/\/doi.org\/10.1038\/tpj.2016.47","DOI":"10.1038\/tpj.2016.47"},{"key":"2026051108215244379_j_acph-2023-0018_ref_034","doi-asserted-by":"crossref","unstructured":"J. Mennis, G. J. Stahler and M. J. Mason, Risky substance use environments and addiction: A new frontier for environmental justice research, Int. J. Environ. Res. Public Health 13(6) (2016) Article ID 607 (15 pages); https:\/\/doi.org\/10.3390\/ijerph13060607","DOI":"10.3390\/ijerph13060607"},{"key":"2026051108215244379_j_acph-2023-0018_ref_035","doi-asserted-by":"crossref","unstructured":"M. Gosch, B. B\u00f6hmdorfer, U. Benvenuti-Falger, P. Dovjak, B. Iglseder, M. Lechleitner, R. Otto, R. E. Roller and U. Sommeregger, [Polypharmacy and pain treatment], Wien. Med. Wochenschr. 160(11\u201312) (2010) 286\u2013292; https:\/\/doi.org\/10.1007\/s10354-010-0788-z","DOI":"10.1007\/s10354-010-0788-z"},{"key":"2026051108215244379_j_acph-2023-0018_ref_036","doi-asserted-by":"crossref","unstructured":"A. I. Henche Ruiz, Problematic use of prescription opioid drugs: Classification and effective treatments, Med. Clin. 152(11) (2019) 458\u2013465; https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.medcli.2018.10.008","DOI":"10.1016\/j.medcle.2019.04.010"},{"key":"2026051108215244379_j_acph-2023-0018_ref_037","doi-asserted-by":"crossref","unstructured":"M. D. Cheatle, P. A. Compton, L. Dhingra, T. E. Wasser and C. P. O\u2019Brien, Development of the revised opioid risk tool to predict opioid use disorder in patients with chronic nonmalignant pain, J. Pain 20(7) (2019) 842\u2013851; https:\/\/doi.org\/10.1016\/j.jpain.2019.01.011","DOI":"10.1016\/j.jpain.2019.01.011"},{"key":"2026051108215244379_j_acph-2023-0018_ref_038","doi-asserted-by":"crossref","unstructured":"C. Els, T. D. Jackson, D. Kunyk, V. G. Lappi, B. Sonnenberg, R. Hagtvedt, S. Sharma, F. Kolahdooz and S. Straube, Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane reviews, Cochrane Database Syst. Rev. 10(10) (2017) Cd012509; https:\/\/doi.org\/10.1002\/14651858.CD012509.pub2","DOI":"10.1002\/14651858.CD012509"},{"key":"2026051108215244379_j_acph-2023-0018_ref_039","doi-asserted-by":"crossref","unstructured":"L. Hazell and S. A. Shakir, Under-reporting of adverse drug reactions: a systematic review, Drug Safety 29(5) (2006) 385\u2013396; https:\/\/doi.org\/10.2165\/00002018-200629050-00003","DOI":"10.2165\/00002018-200629050-00003"},{"key":"2026051108215244379_j_acph-2023-0018_ref_040","doi-asserted-by":"crossref","unstructured":"M. Gombert, P. Ballester, A. Segura and A. M. Peir\u00f3, Introducing sexual dysfunction in mental care, Expert Opin. Drug Safety 20(1) (2021) 69\u201379; https:\/\/doi.org\/10.1080\/14740338.2020.1849135","DOI":"10.1080\/14740338.2020.1849135"},{"key":"2026051108215244379_j_acph-2023-0018_ref_041","doi-asserted-by":"crossref","unstructured":"L. LeResche, K. Saunders, S. Dublin, S. Thielke, J. O. Merrill, S. M. Shortreed, C. Campbell and M. R. Von Korff, Sex and age differences in global pain status among patients using opioids long term for chronic noncancer pain, J. Women Health 24(8) (2015) 629\u2013635; https:\/\/doi.org\/10.1089\/jwh.2015.5222","DOI":"10.1089\/jwh.2015.5222"},{"key":"2026051108215244379_j_acph-2023-0018_ref_042","doi-asserted-by":"crossref","unstructured":"M. Noble, J. R. Treadwell, S. J. Tregear, V. H. Coates, P. J. Wiffen, C. Akafomo, K. M. Schoelles and R. Chou, Long-term opioid management for chronic noncancer pain, Cochrane Database Syst. Rev. No. 1 (2010) CD006605; https:\/\/doi.org\/10.1002\/14651858.CD006605.pub2","DOI":"10.1002\/14651858.CD006605.pub2"},{"key":"2026051108215244379_j_acph-2023-0018_ref_043","doi-asserted-by":"crossref","unstructured":"N. Kozlov and H. T. Benzon, Role of gender and race in patient-reported outcomes and satisfaction, Anesthesiol. Clin. 38(2) (2020) 417\u2013431; https:\/\/doi.org\/10.1016\/j.anclin.2020.01.012","DOI":"10.1016\/j.anclin.2020.01.012"},{"key":"2026051108215244379_j_acph-2023-0018_ref_044","doi-asserted-by":"crossref","unstructured":"F. K. H. S\u00f8rup, R. Eriksson, D. Westergaard, J. Hallas, S. Brunak and S. E. Andersen, Sex differences in text-mined possible adverse drug events associated with drugs for psychosis, J. Psycho-pharmacol. (Oxford) 34(5) (2020) 532\u2013539; https:\/\/doi.org\/10.1177\/0269881120903466","DOI":"10.1177\/0269881120903466"},{"key":"2026051108215244379_j_acph-2023-0018_ref_045","doi-asserted-by":"crossref","unstructured":"E. Mura, S. Govoni, M. Racchi, V. Carossa, G. N. Ranzani, M. Allegri and R. H. van Schaik, Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?, J. Pain Res. 6 (2013) 331\u2013353; https:\/\/doi.org\/10.2147\/jpr.s42040","DOI":"10.2147\/JPR.S42040"},{"key":"2026051108215244379_j_acph-2023-0018_ref_046","doi-asserted-by":"crossref","unstructured":"K. Blum, M. Oscar-Berman, Z. Demetrovics, D. Barh and M. S. Gold, Genetic addiction risk score (GARS): molecular neurogenetic evidence for predisposition to reward deficiency syndrome (RDS), Mol. Neurobiol. 50(3) (2014) 765\u2013796; https:\/\/doi.org\/10.1007\/s12035-014-8726-5","DOI":"10.1007\/s12035-014-8726-5"},{"key":"2026051108215244379_j_acph-2023-0018_ref_047","unstructured":"L. Dean and M. Kane, Codeine Therapy and CYP2D6 Genotype, in Medical Genetics Summaries (Eds. V. M. Pratt, S. A. Scott, M. Pirmohamed, B. Esquivel, M. S. Kane, B. L. Kattman and A. J. Malheiro), National Center for Biotechnology Information, Bethesda (MD) 2012, p. 25."},{"key":"2026051108215244379_j_acph-2023-0018_ref_048","doi-asserted-by":"crossref","unstructured":"E. B. Ettienne, A. Ofoegbu, M. K. Maneno, J. Briggs, G. Ezeude, S. Williams, C. Walker and E. Chapman, Pharmacogenomics and opioid use disorder: clinical decision support in an African American cohort, J. Nat. Med. Assoc. 111(6) (2019) 674\u2013681; https:\/\/doi.org\/10.1016\/j.jnma.2019.09.006","DOI":"10.1016\/j.jnma.2019.09.006"},{"key":"2026051108215244379_j_acph-2023-0018_ref_049","doi-asserted-by":"crossref","unstructured":"M. A. Bahar, D. Setiawan, E. Hak and B. Wilffert, Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6, Pharmacogenomics 18(7) (2017) 701\u2013739; https:\/\/doi.org\/10.2217\/pgs-2017-0194","DOI":"10.2217\/pgs-2017-0194"},{"key":"2026051108215244379_j_acph-2023-0018_ref_050","doi-asserted-by":"crossref","unstructured":"C. R. Fulton, Y. Zang, Z. Desta, M. B. Rosenman, A. M. Holmes, B. S. Decker, Y. Zhang, J. T Callaghan, V. M. Pratt, K. D. Levy, B. T. Gufford, P. R. Dexter, T. C. Skaar and M. T. Eadon, Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial, Pharmacogenomics 20(6) (2019) 397\u2013408; https:\/\/doi.org\/10.2217\/pgs-2018-0205","DOI":"10.2217\/pgs-2018-0205"},{"key":"2026051108215244379_j_acph-2023-0018_ref_051","doi-asserted-by":"crossref","unstructured":"G. Cochran, J. Bruneau, N. Cox and A. J. Gordon, Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic, Subst. Abuse 41(3) (2020) 269\u2013274; https:\/\/doi.org\/10.1080\/08897077.2020.1787300","DOI":"10.1080\/08897077.2020.1787300"},{"key":"2026051108215244379_j_acph-2023-0018_ref_052","unstructured":"National Institute on Drug Abuse (NIDA), Cooperation Between Physicians and Pharmacists May Improve Treatment for Patients with Opioid Use Disorder, 2021; https:\/\/nida.nih.gov\/news-events\/nida-notes\/2021\/11\/cooperation-between-physicians-and-pharmacists-may-improve-treatment-for-patients-with-opioid-use-disorder; last access date September 20, 2022"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/acph-2023-0018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:01:01Z","timestamp":1778490061000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/acph-2023-0018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,6,12]]},"published-print":{"date-parts":[[2023,6,1]]}},"alternative-id":["10.2478\/acph-2023-0018"],"URL":"https:\/\/doi.org\/10.2478\/acph-2023-0018","relation":{},"ISSN":["1846-9558"],"issn-type":[{"value":"1846-9558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}